- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.10. | Elutia erhält 8 Millionen US-Dollar aus Treuhandkonto von Boston Scientific | 11 | Investing.com Deutsch | ||
| ELUTIA Aktie jetzt für 0€ handeln | |||||
| 01.10. | Elutia receives $8 million escrow from Boston Scientific sale | 3 | Investing.com | ||
| 01.10. | Elutia Inc.: Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029 | 268 | GlobeNewswire (Europe) | Boston Scientific released the full $8 million holdback on schedule and with no claimsEscrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its... ► Artikel lesen | |
| 21.08. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.08. | Elutia Flat on Sale to Cellution | 1 | Baystreet.ca | ||
| 18.08. | Elutia sells SimpliDerm business for up to $11 million | 2 | Investing.com | ||
| 18.08. | Elutia Inc.: Elutia Completes SimpliDerm Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch | 3 | GlobeNewswire (USA) | ||
| 14.08. | ELUTIA INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 14.08. | Elutia anticipates NXT-41x clearance in 1H 2027 while targeting >80% gross margins at scale | 1 | Seeking Alpha | ||
| 14.08. | Elutia Q2 2026 slides: $26M capital raise funds NXT41x launch | 1 | Investing.com | ||
| 14.08. | Elutia Q2 2026 Earnings Call Transcript | 1 | Benzinga.com | ||
| 13.08. | Elutia GAAP EPS of -$0.17 misses by $0.02, revenue of $2.4M misses by $0.5M | 1 | Seeking Alpha | ||
| 13.08. | Elutia sichert sich 26 Mio. USD Kapital vor wichtiger FDA-Entscheidung | 2 | Investing.com Deutsch | ||
| 13.08. | Elutia secures $26M in capital, expects FDA decision on NXT-41 | 1 | Investing.com | ||
| 13.08. | Elutia secures $15 million financing for product development | 1 | Investing.com | ||
| 13.08. | Elutia Inc.: Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results | 197 | GlobeNewswire (Europe) | Funded through launch: secured up to $26 million of capital without an equity offeringThe unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection riskThe demand... ► Artikel lesen | |
| 07.08. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 31.07. | Elutia Inc.: Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026 | 1 | GlobeNewswire (USA) | ||
| 20.07. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.07. | Elutia Sheds Legacy Business to Chase $1.5 Billion Market Opportunity | 3 | Benzinga.com |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ENLIVEX | 0,200 | -13,04 % | Enlivex Ltd.: Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion | - As of July 18, 2026, net asset value (NAV1) per share was $66.16 - As of July 18, 2026, Enlivex held 79,550,593,122 RAIN tokens with a total value of approximately $1.1 billion2- Nes-Ziona... ► Artikel lesen | |
| CARIBOU BIOSCIENCES | 0,460 | 0,00 % | Caribou Biosciences, Inc.: Caribou Biosciences to Evaluate Strategic Alternatives | -- Company to evaluate strategic alternatives to maximize stockholder value -- -- Caribou plans to discontinue vispa-cel and CB-011 allogeneic CAR-T cell therapy programs -- -- Cash, cash equivalents... ► Artikel lesen | |
| BIOAFFINITY TECHNOLOGIES | 4,725 | 0,00 % | bioAffinity Technologies, Inc. - 8-K, Current Report | ||
| ARRIVENT BIOPHARMA | 16,710 | -0,12 % | Fierce Pharma Asia-Novartis' $7.8B mRNA deal; Shionogi's $2B buy; ArriVent's phase 3 flop | ||
| FOGHORN THERAPEUTICS | 2,010 | +0,50 % | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities | Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader programCompany to focus resources on wholly owned pipeline, including a Selective... ► Artikel lesen | |
| TELA BIO | 1,110 | 0,00 % | TELA Bio, Inc.: TELA Bio Announces 510(k) Clearance for Liora Monofilament Scaffold for Soft Tissue Reinforcement | MALVERN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| SURROZEN | 29,565 | -0,42 % | Surrozen, Inc.: Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema | First patient expected to be dosed in the DUET study in the fourth quarter of 2026 Milestone triggers second closing of March 2025 private placement expected to provide approximately $95.1M in gross... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 259,86 | 0,00 % | Praxis Precision Medicine Q2 2026 Earnings Call Transcript | ||
| ERASCA | 16,030 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,590 | 0,00 % | Summit Therapeutics Secures $2B Strategic Investment From AstraZeneca | LONDON (dpa-AFX) - Summit Therapeutics Inc. (SMMT) on Monday announced the closing of AstraZeneca's (AZN) $2 billion strategic equity investment, which will support accelerated development of... ► Artikel lesen | |
| QIAGEN | 40,190 | +1,55 % | Pharma-Aktien starten durch: Merck, Qiagen und Bayer im Höhenflug - KI-Boom und US-Megadeal befeuern Branche | Die Aktien von Pharma- und Biotech-Unternehmen erleben am Dienstag einen starken Aufwärtstrend, angeführt von Merck KGaA. Investoren setzen auf Übernahmespekulationen und den KI-getriebenen Innovationsschub... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,360 | 0,00 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| KINIKSA PHARMACEUTICALS | 79,78 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| MODERNA | 200,50 | -0,17 % | Moderna-Aktie: Steht der Ausbruch bevor? | Die Moderna-Aktie setzt ihre spektakuläre Erholung fort und notiert bei 190,01 US$. Damit hat der Kurs der Moderna-Aktie eine mehrjährige Widerstandszone überwunden. Der Ausbruch eröffnet technisch... ► Artikel lesen | |
| NURIX THERAPEUTICS | 22,350 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia | First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation... ► Artikel lesen |
Das Unternehmen ELUTIA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,823 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELUTIA INC finden Sie auf Wallstreet Online.